Xeris Pharmaceuticals (XERS)
(Delayed Data from NSDQ)
$7.72 USD
-0.58 (-6.99%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $7.70 -0.02 (-0.26%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
XERS 7.72 -0.58(-6.99%)
Will XERS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for XERS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XERS
What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?
Xeris Biopharma (XERS) Upgraded to Buy: Here's Why
XERS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?
Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
Other News for XERS
Is XERS showing upside potential? Crossed Above 20 Day Moving Average shows up after surging 8.21%
Stochastic Buy Signal appears for XERS after 2.68% move
Xeris Pharmaceuticals (XERS) Receives a Buy from H.C. Wainwright
Bollinger Band Squeeze appears for XERS after 1.49% move
XERS forms Stochastic Reached Oversold on September 15